

Somatostatin analogue associated gallstones

SUPPLEMENTARY MATERIAL

Aapkes, S.E., de Haas, R.J., Bernts, L.H.P., Blijdorp, C.J., Dekker, S.E.I., van Gastel, M.D.A., Meijer, E. Veldman, A., Drenth, J.P.H., Gansevoort, R.T. Incident gallstones during somatostatin analogue treatment are associated with acute biliary complications especially after discontinuation. Drug Safety

Correspondence:

Prof. R.T. Gansevoort, Department of Nephrology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. Phone: +3150 3616161, email:

r.t.gansevoort@umcg.nl

Supplementary table 1: Incidence of symptoms possibly indicative of gallstones in ADPKD patients treated with lanreotide with and without incident gallstones during treatment.

Patients treated with lanreotide	Incident gallstones during study N (%)	No incident gallstones during study (N%)	<i>P</i> value
Symptoms			
Abdominal cramps	11 (57.9)	50 (47.6)	0.41
Abdominal pain	9 (47.4)	39 (37.1)	0.40
Discolored stool	10 (52.6)	52 (49.5)	0.80
Hepatic cyst infection	0 (0)	6 (5.7)	0.29

Supplementary Fig. 1. Treatment duration, discontinuation, and time until complication

